Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ET
Company Participants
Christopher R. Fenimore – Executive VP of Finance & CFO
Ryan Crowe – Senior Vice President of Investor Relations & Strategic Analysis
Conference Call Participants
Salveen Jaswal Richter – Goldman Sachs Group, Inc., Research Division
Salveen Jaswal Richter
Great. Good morning, everyone. Thank you for joining us. I’m Salveen Richter, biotechnology analyst at Goldman Sachs. I’m really pleased to be joined by the Regeneron team. Next to me is Chris Fenimore, Head of Finance and CFO; and Ryan Crowe, Head of IR and Strategic Analysis. So to start here, actually, Ryan, let me turn it over to you because I think you have some opening comments.
Ryan Crowe
Yes. Just some forward-looking statement business to take care of here. I’d like to remind you that remarks made today may include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron’s SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. With that, Salveen, let’s get into the important part of the talk.
Question-and-Answer Session
Salveen Jaswal Richter
Perfect. So to get started here, I think it’d be helpful to frame for us how you see the company positioned today with the current EYLEA franchise dynamics, the Dupixent outlook and the late-stage pipeline and where you are most focused from a strategy and execution standpoint over the next 12 to 18 months?
Christopher R. Fenimore
Sure. Thanks, Salveen. For us, as we execute on our strategy, there’s two things that are core
